Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.06 EUR
Change Today -0.001 / -1.61%
Volume 32.3K
SBH On Other Exchanges
As of 2:21 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

sangui biotech intl inc (SBH) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/14 - €0.12
52 Week Low
01/23/15 - €0.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANGUI BIOTECH INTL INC (SBH)

Related News

No related news articles were found.

sangui biotech intl inc (SBH) Related Businessweek News

No Related Businessweek News Found

sangui biotech intl inc (SBH) Details

Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. Its artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss. The company also offers nano formulations for the regeneration of skin, including moisturization of the skin and enhanced skin elasticity; offers Chitoskin wound pads for supporting wound healing; Hemospray wound spray, a medical product that is used for the healing of chronic wounds; and cosmetic products. It sells its wound spray product under the Granulox brand name in Europe and Mexico; and cosmetic products through Internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is based in Witten, Germany.

1 Employees
Last Reported Date: 09/25/14
Founded in 1995

sangui biotech intl inc (SBH) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: --
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $37.3K
Compensation as of Fiscal Year 2014.

sangui biotech intl inc (SBH) Key Developments

Sangui Biotech Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2014

Sangui Biotech reported earnings results for the second quarter and six months ended December 31, 2014. In the second quarter revenues amounted to USD 31,166 a decrease of 57.7% as compared with the most recent quarter. For the first half of its 2015 financial year the company reported revenues from product sales and royalties in the amount of USD 104,906 an increase of 74.0% over the revenues in the first half of the financial year 2014.

Sangui Biotech International Inc. Reports Unaudited Revenue Results for the Second Quarter and Six Months of 2015

Sangui Biotech International Inc. reported unaudited revenue results for the second quarter and six months of 2015. For the quarter, the company yielded revenues from royalties and product sales of more than USD 31,000 in the course of the second quarter of its financial year 2015, ended December 31, 2014. In the second quarter of its financial year 2014 (ended December 31, 2013) the company reported revenues of USD 33,776. Revenues in the first six months of the 2015 financial year amounted to approximately USD 105,000 after USD 60,303 in the respective period of the previous year.

Sangui Biotech International, Inc. Announces Earnings Results for the First Quarter Ended September 30, 2014

Sangui BioTech International Inc. announced earnings results for the first quarter ended September 30, 2014. For the first quarter of its 2015 financial year, the company reported revenues from product sales and royalties in the amount of USD 73,470 against USD 26,527 a year ago. This is an improvement of 73% as compared with the fourth quarter of the previous financial year. The net loss attributable to shareholders of the parent company came to USD 194,168 against USD 172.202 a year ago, the cash outflow from operations during the quarter amounted to USD 207,675 against USD 189,860 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBH:GR €0.06 EUR -0.001

SBH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBH.
View Industry Companies

Industry Analysis


Industry Average

Valuation SBH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 55.3x
Price/Book 21.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 58.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANGUI BIOTECH INTL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at